國立虎尾科技大學 |

Regulatory and Economic Aspects in Oncology

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Regulatory and Economic Aspects in Oncology/ edited by Evelyn Walter.
其他作者:	Walter, Evelyn.
面頁冊數:	VII, 205 p. 14 illus., 12 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology . -
電子資源:	https://doi.org/10.1007/978-3-030-01207-6
ISBN:	9783030012076

Regulatory and Economic Aspects in Oncology
Regulatory and Economic Aspects in Oncology[electronic resource] /edited by Evelyn Walter. - 1st ed. 2019. - VII, 205 p. 14 illus., 12 illus. in color.online resource. - Recent Results in Cancer Research,2130080-0015 ;. - Recent Results in Cancer Research,200.

The growing health burden of cancer: a global epidemiological overview.-Cost of Cancer Care: Health expenditures and economic impact -- Innovation in R&D: An answer to cancer -- The Evaluation of Benefits, Harms and Costs of Cancer Screening -- Oncology from a HTA and health economic perspective -- Heterogeneous recommendations for oncology products among different HTA systems: a comparative assessment -- Outcomes in oncology: clinical vs. patient-reported outcome performance measures -- The value of patient-reported outcome in health economic decision making: a changing landscape in oncology -- Approaches to capture value in oncology -- Orphan durgs in oncology -- Recent developments in health economic modeling of cancer therapies -- Drug pricing and value in oncology -- Pharmaceutical price regulation of cancer treatments -- Regulatory and evidence requirements and the changing landscape in regulation for marketing authorization -- Looking for Willingness to Pay (WTP) Threshold for a QALY in oncology -- Equity and patient access to innovative cancer treatments. .

This book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society’s willingness to pay.

ISBN: 9783030012076

Standard No.: 10.1007/978-3-030-01207-6doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Regulatory and Economic Aspects in Oncology
LDR:03801nam a22003975i 4500 001 1015348
003 DE-He213
005 20200705200907.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030012076 $9 978-3-030-01207-6
024 7 $a 10.1007/978-3-030-01207-6 $2 doi
035 $a 978-3-030-01207-6
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Regulatory and Economic Aspects in Oncology $h [electronic resource] / $c edited by Evelyn Walter.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VII, 205 p. 14 illus., 12 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 213
505 0 $a The growing health burden of cancer: a global epidemiological overview.-Cost of Cancer Care: Health expenditures and economic impact -- Innovation in R&D: An answer to cancer -- The Evaluation of Benefits, Harms and Costs of Cancer Screening -- Oncology from a HTA and health economic perspective -- Heterogeneous recommendations for oncology products among different HTA systems: a comparative assessment -- Outcomes in oncology: clinical vs. patient-reported outcome performance measures -- The value of patient-reported outcome in health economic decision making: a changing landscape in oncology -- Approaches to capture value in oncology -- Orphan durgs in oncology -- Recent developments in health economic modeling of cancer therapies -- Drug pricing and value in oncology -- Pharmaceutical price regulation of cancer treatments -- Regulatory and evidence requirements and the changing landscape in regulation for marketing authorization -- Looking for Willingness to Pay (WTP) Threshold for a QALY in oncology -- Equity and patient access to innovative cancer treatments. .
520 $a This book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society’s willingness to pay.
650 0 $a Oncology . $3 1253469
650 0 $a Health administration. $3 1105247
650 1 4 $a Oncology. $3 593951
650 2 4 $a Health Administration. $3 677396
700 1 $a Walter, Evelyn. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1309473
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030012069
776 0 8 $i Printed edition: $z 9783030012083
830 0 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 200 $3 1263334
856 4 0 $u https://doi.org/10.1007/978-3-030-01207-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)